Qiagen stock holds steady as 2026 guidance and margins stay central

Qiagen (NL0012169213) stock remains centered on its 2026 outlook after the company said it expects full-year net sales growth of 4% to 5% and adjusted diluted earnings per share of $2.35 to $2.45 for 2026. In the companys Q1 2026 update, Qiagen reported net sales of $483 million and adjusted diluted EPS of $0.56, giving investors a dated reference point for the current trading setup.

2026 guidance still matters

The Q1 2026 numbers frame the stock more clearly than a headline price move. Qiagen said adjusted operating income reached $126 million in Q1 2026, while adjusted operating income margin came in at 26.1%, which helps explain why the full-year earnings range remains the main market focus.

That margin was higher than the 25.3% reported in Q1 2025, a year-over-year gain of 0.8 percentage points. The same update put reported diluted EPS at $0.24 in Q1 2026, versus $0.20 in Q1 2025, while adjusted diluted EPS rose to $0.56 from $0.53.

Q1 sales set the baseline

Qiagen said its Q1 2026 net sales of $483 million were driven by a return to growth in key product areas, with the company guiding for a stronger full year in 2026. The gap between the quarter and the annual forecast leaves the market watching execution more than narrative.

The company also said it continues to expect a mid-single-digit constant-currency sales increase for 2026, which aligns with the 4% to 5% revenue range in its published outlook. For investors, that makes each quarterly print a test of whether the guidance can hold through the rest of the year.

QuantiFERON remains a core product

One of Qiagens best-known products is QuantiFERON, the companys tuberculosis test line. The product family is tied to the companys broader Sample to Insight business model, and it remains relevant because recurring diagnostic volumes can influence the sales mix quarter by quarter.

Qiagen has repeatedly used its IR updates to link product demand to group revenue and margin development, which is why the companys product mix matters alongside the headline earnings range. The Q1 2026 margin of 26.1% and the full-year adjusted EPS range of $2.35 to $2.45 are the figures that best capture that relationship.

Trading level and valuation lens

A dated market price was not provided in the available search results, so the clearest market-value reference is the companys 2026 guidance and Q1 2026 performance. The stock story is therefore about whether sales growth of 4% to 5% and adjusted diluted EPS of $2.35 to $2.45 can be sustained after a first quarter of $483 million in net sales.

Qiagens next earnings update will matter most if it confirms the margin path established in Q1 2026. Until then, the stock is being judged against the combination of 26.1% adjusted operating margin, $0.56 adjusted diluted EPS, and the companys full-year outlook.